These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 7273010

  • 1. Chemotherapy for colorectal cancer with a combination of PALA and 5-FU.
    Bedikian AY, Stroehlein JR, Karlin DA, Bennetts RW, Bodey GP, Valdivieso M.
    Cancer Treat Rep; 1981; 65(9-10):747-53. PubMed ID: 7273010
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
    Buroker TR, Moertel CG, Fleming TR, Everson LK, Cullinan SA, Krook JE, Mailliard JA, Marschke RF, Klaassen DJ, Laurie JA.
    J Clin Oncol; 1985 Dec; 3(12):1624-31. PubMed ID: 2933492
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of PALA on the pharmacokinetics of 5-fluorouracil.
    Nassim MA, Rouini MR, Cripps MC, Shirazi FH, Veerasinghan S, Molepo JM, Obrocea M, Redmond D, Bates S, Fry D, Stewart DJ, Goel R.
    Oncol Rep; 1998 Dec; 5(1):217-21. PubMed ID: 9458325
    [Abstract] [Full Text] [Related]

  • 11. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
    Casper ES, Vale K, Williams LJ, Martin DS, Young CW.
    Cancer Res; 1983 May; 43(5):2324-9. PubMed ID: 6831457
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
    Fleming RA, Capizzi RL, Muss HB, Smith S, Fernandes DJ, Homesley H, Loggie BW, Case L, Morris R, Russell GB, Richards F.
    Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
    [Abstract] [Full Text] [Related]

  • 14. Pilot study of PALA and 5-FU in patients with advanced cancer.
    O'Connell MJ, Powis G, Rubin J, Moertel CG.
    Cancer Treat Rep; 1982 Jan; 66(1):77-80. PubMed ID: 7053270
    [Abstract] [Full Text] [Related]

  • 15. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
    Ardalan B, Ucar A, Reddy R, Livingstone AS, Markoe A, Schwade J, Richman SP, Donofrio K.
    Cancer; 1994 Oct 01; 74(7):1869-73. PubMed ID: 8082092
    [Abstract] [Full Text] [Related]

  • 16. Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma.
    O'Connell MJ, Moertel CG, Rubin J, Hahn RG, Kvols LK, Schutt AJ.
    J Clin Oncol; 1984 Oct 01; 2(10):1133-8. PubMed ID: 6491697
    [Abstract] [Full Text] [Related]

  • 17. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL, McAtee N, Steinberg SM, Hamilton JM, Murphy RF, Drake J, Chisena T, Balis F, Cysyk R, Arbuck SG.
    Cancer Res; 1993 Oct 15; 53(20):4828-36. PubMed ID: 8402669
    [Abstract] [Full Text] [Related]

  • 18. Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
    Carroll DS, Gralla RJ, Kemeny NE.
    Cancer Treat Rep; 1980 Oct 15; 64(2-3):349-51. PubMed ID: 7407769
    [No Abstract] [Full Text] [Related]

  • 19. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
    O'Dwyer PJ, Paul AR, Walczak J, Weiner LM, Litwin S, Comis RL.
    J Clin Oncol; 1990 Sep 15; 8(9):1497-503. PubMed ID: 2391557
    [Abstract] [Full Text] [Related]

  • 20. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
    Van Echo DA, Diggs CH, Scoltock M, Wiernik PH.
    Cancer Treat Rep; 1980 Sep 15; 64(2-3):339-42. PubMed ID: 7407767
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.